[A18-30] Alectinib (non-small-cell lung cancer) - Addendum to Commission A17-67
Last updated 21.06.2018
Project no.:
A18-30
Commission:
Commission awarded on 08.05.2018 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
First-line treatment of adults with ALK-positive advanced NSCLC (lung cancer)
Result of dossier assessment:
Conclusion of dossier assessment A17-67 unchanged
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A17-67 | Alectinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-06-21 A G-BA decision was published.